Page 140 - SRPSKO DRUŠTVO ISTRAŽIVAČA RAKA

Serbian Association for Cancer Research SDIRSACR

4. Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin
Oncol 2010 Mar 1;28(7):1254–61.
5. Pascual J, Attard G, Bidard FC, Curigliano G, De Mattos-Arruda L, Diehn M, et al. ESMO recommendations on the
use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working
Group. Ann Oncol 2022 Aug;33(8):750–68.
6. Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et al. ESMO consensus guidelines for
the management of patients with metastatic colorectal cancer [Internet]. ResearchGate. 2016 [cited 2025 Aug 30].
Available from:https://www.researchgate.net/publication/304907923_ESMO_consensus_guidelines_for_the_
management_of_patients_with_metastatic_colorectal_cancer
7. Schirripa M, Lenz HJ. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.
Int J Cancer [Internet]. 2015 [cited 2025 Aug 30]. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/
ijc.28955
8. Leto SM, Trusolino L. Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on
future treatment strategies. J Mol Med (Berl). 2014 Jul;92(7):709–22.

125